Navigation Links
Cancer Risk After Kidney Transplant Unaffected by Type of Drug Treatment
Date:4/29/2010

Risk similar from all drugs used to prevent organ rejection, researchers find

THURSDAY, April 29 (HealthDay News) -- The type of drug treatment used to prevent organ rejection in kidney transplant patients doesn't affect cancer risk, a new study finds.

Kidney transplant patients are at increased risk for cancer, likely because of patients' long-term use of immunosuppressive drugs to prevent organ rejection. In this study, Australian researchers examined the incidence of cancer in 481 kidney transplant patients.

The patients had received one of three treatment regimens: azathioprine and prednisolone; cyclosporine monotherapy; or cyclesoporine monotherapy followed by a switch to azathioprine and prednisolone after three months.

In the 20 years after transplant, 226 patients developed at least one cancer, including 48 percent who developed skin cancer and 27 percent who developed non-skin cancer. None of the anti-rejection treatments had a greater effect than another on cancer timing or incidence.

The findings indicate that "any differences in cancer risk from these different treatments are unlikely to be clinically significant," said study author Martin Gallagher, of the George Institute for International Health in Australia.

He and his colleagues also found that kidney transplant recipients' increased risk of cancer is significantly influenced by certain characteristics at the time of transplant. For example, non-skin cancer is associated with increasing age and previous smoking history, while skin cancer is associated with increasing age, non-brown eye color, fairer skin, and a functioning transplant.

High-risk patients need to be monitored more closely and use preventive measures to protect against cancer, the researchers said.

The study appears in the April 29 issue of the Journal of the American Society of Nephrology.

More information

The National Kidney Foundation has more about reducing cancer risk after a kidney transplant.



-- Robert Preidt



SOURCE: American Society of Nephrology, news release, April 29, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Cells programmed to cure and even prevent cancer
2. FDA Approval of new Prostate Treatment Shows Promise of Cancer Immunotherapy
3. Prostate Cancer Vaccine Gains FDA Approval
4. CXCR4: A new drug target in lung cancer
5. Best care for the oldest lung cancer patients
6. Curcumin nanoparticles open up resistant cancers
7. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
8. Breakthrough in Predicting Invasive Breast Cancer
9. Comparison of available breast cancer risk assessment tools shows room for improvement
10. Breakthrough method predicts risk of invasive breast cancer
11. Researchers attack stem cells that cause colon cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... , ... As health professionals work to improve their approach to healthcare, there ... more than filling out a survey; in many cases health professionals and patients are ... care and research on the importance of active engagement with patients and members of ...
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... a national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel ... also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
Breaking Medicine Technology: